These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11288500)

  • 1. Bone loss in adolescents using Depo-Provera.
    Kass-Wolff JH
    J Soc Pediatr Nurs; 2001; 6(1):21-31. PubMed ID: 11288500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depo-Provera and bone density.
    Gbolade BA
    J Fam Plann Reprod Health Care; 2002 Jan; 28(1):7-11; quiz 11, 50. PubMed ID: 16259806
    [No Abstract]   [Full Text] [Related]  

  • 3. Depo-Provera: new concerns--same issues?
    Robinson K
    AWHONN Lifelines; 2005; 9(3):214-7. PubMed ID: 16114743
    [No Abstract]   [Full Text] [Related]  

  • 4. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives.
    Cromer BA; Blair JM; Mahan JD; Zibners L; Naumovski Z
    J Pediatr; 1996 Nov; 129(5):671-6. PubMed ID: 8917232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of DMPA by adolescents.
    Gold MA; Hertweck SP; Lara-Torre E
    J Pediatr Adolesc Gynecol; 2005 Dec; 18(6):435-7. PubMed ID: 16338614
    [No Abstract]   [Full Text] [Related]  

  • 6. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term depot-medroxyprogesterone acetate and bone mineral density.
    Tang OS; Tang G; Yip P; Li B; Fan S
    Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral density.
    Johnson CC; Burkman RT; Gold MA; Brown RT; Harel Z; Bruner A; Stager M; Bachrach LK; Hertweck SP; Nelson AL; Nelson DA; Coupey SM; McLeod A; Bone HG
    Contraception; 2008 Apr; 77(4):239-48. PubMed ID: 18342646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DMPA's effect on bone mineral density: A particular concern for adolescents.
    Schrager SB
    J Fam Pract; 2009 May; 58(5):E1-8. PubMed ID: 19442384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age.
    Gai L; Zhang J; Zhang H; Gai P; Zhou L; Liu Y
    Contraception; 2011 Mar; 83(3):218-22. PubMed ID: 21310282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate.
    Modesto W; Bahamondes MV; Silva dos Santos P; Fernandes A; Dal'Ava N; Bahamondes L
    Eur J Contracept Reprod Health Care; 2014 Aug; 19(4):244-9. PubMed ID: 24923792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depot medroxyprogesterone and bone mineral density.
    Ryan PJ; Singh SP; Guillebaud J
    J Fam Plann Reprod Health Care; 2002 Jan; 28(1):12-5. PubMed ID: 16259808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.
    Wooltorton E
    CMAJ; 2005 Mar; 172(6):746. PubMed ID: 15743913
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
    Modesto W; Bahamondes MV; Bahamondes L
    J Womens Health (Larchmt); 2015 Aug; 24(8):636-40. PubMed ID: 26098552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is poor nutrition masking the effects of depomedroxyprogesterone acetate on bones in adolescent users?
    Rianon NJ; Britt RB; Faisel AJ; Shahidullah SM; Leblanc AD
    Singapore Med J; 2010 Nov; 51(11):876-82. PubMed ID: 21140115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.
    Polaneczky M; Liblanc M
    J Adolesc Health; 1998 Aug; 23(2):81-8. PubMed ID: 9714170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.